Genetic Variant as a Selection Marker for Anti–Prostate Stem Cell Antigen Immunotherapy of Bladder Cancer

A monoclonal antibody against prostate stem cell antigen (PSCA) has emerged as a novel cancer therapy currently being tested in clinical trials for prostate and pancreatic cancers, but this treatment is likely to be efficient only in patients with PSCA-expressing tumors. The present study demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohaar, Indu, Porter-Gill, Patricia, Lenz, Petra, Fu, Yi-Ping, Mumy, Adam, Tang, Wei, Apolo, Andrea B., Rothman, Nathaniel, Baris, Dalsu, Schned, Alan R., Ylaya, Kris, Schwenn, Molly, Johnson, Alison, Jones, Michael, Kida, Masatoshi, Silverman, Debra T., Hewitt, Stephen M., Moore, Lee E., Prokunina-Olsson, Ludmila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536639/
https://www.ncbi.nlm.nih.gov/pubmed/23266392
http://dx.doi.org/10.1093/jnci/djs458

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536639/
https://www.ncbi.nlm.nih.gov/pubmed/23266392
http://dx.doi.org/10.1093/jnci/djs458

Ejemplares similares